United States: These 37 Drugs Face Patent Expirations and Generic Entry From 2023 - 2024

Generic name: levalbuterol tartrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2023
Generic Entry Controlled by: United States Patent Patent 8,765,153

XOPENEX HFA is a drug marketed by Lupin. There are two patents protecting this drug.

This drug has thirty-six patent family members in eighteen countries. There has been litigation on patents covering XOPENEX HFA

See drug price trends for XOPENEX HFA.

The generic ingredient in XOPENEX HFA is levalbuterol tartrate. There are nine drug master file entries for this API. Five suppliers are listed for this generic product. Additional details are available on the levalbuterol tartrate profile page.

Generic name: prucalopride succinate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 14, 2023
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

MOTEGRITY is a drug marketed by Takeda Pharms Usa.

This drug has thirty-six patent family members in eighteen countries.

See drug price trends for MOTEGRITY.

The generic ingredient in MOTEGRITY is prucalopride succinate. One supplier is listed for this generic product. Additional details are available on the prucalopride succinate profile page.

Generic name: peramivir
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 16, 2023
Generic Entry Controlled by: United States Patent Patent 6,562,861

RAPIVAB is a drug marketed by Biocryst. There are three patents protecting this drug.

This drug has seventy patent family members in twenty-eight countries.

See drug price trends for RAPIVAB.

The generic ingredient in RAPIVAB is peramivir. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the peramivir profile page.

Generic name: ferric citrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: February 18, 2024
Generic Entry Controlled by: United States Patent Patent 9,328,133

AURYXIA is a drug marketed by Keryx Biopharms. There are fourteen patents protecting this drug.

This drug has one hundred and twenty-two patent family members in twenty-three countries. There has been litigation on patents covering AURYXIA

See drug price trends for AURYXIA.

The generic ingredient in AURYXIA is ferric citrate. There are twenty drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ferric citrate profile page.

Generic name: esketamine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 05, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SPRAVATO is a drug marketed by Janssen Pharms. There are six patents protecting this drug.

This drug has forty-one patent family members in nineteen countries.

See drug price trends for SPRAVATO.

The generic ingredient in SPRAVATO is esketamine hydrochloride. One supplier is listed for this generic product. Additional details are available on the esketamine hydrochloride profile page.

Generic name: citric acid; lactic acid; potassium bitartrate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 06, 2024
Generic Entry Controlled by: United States Patent Patent 6,706,276

PHEXXI is a drug marketed by Evofem Inc. There are four patents protecting this drug.

This drug has sixty-four patent family members in twenty-three countries.

See drug price trends for PHEXXI.

The generic ingredient in PHEXXI is citric acid; lactic acid; potassium bitartrate. There are five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the citric acid; lactic acid; potassium bitartrate profile page.

Generic name: bupivacaine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: March 22, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EXPAREL is a drug marketed by Pacira Pharms Inc. There are eight patents protecting this drug.

This drug has seven patent family members in four countries. There has been litigation on patents covering EXPAREL

See drug price trends for EXPAREL.

The generic ingredient in EXPAREL is bupivacaine. There are twelve drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the bupivacaine profile page.

Generic name: fentanyl hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 01, 2024
Generic Entry Controlled by: United States Patent Patent 6,975,902

IONSYS is a drug marketed by The Medicines Co. There are eight patents protecting this drug.

This drug has ninety-one patent family members in eighteen countries.

The generic ingredient in IONSYS is fentanyl hydrochloride. There are thirty-one drug master file entries for this API. Additional details are available on the fentanyl hydrochloride profile page.

Generic name: bupropion hydrochloride; naltrexone hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 21, 2024
Generic Entry Controlled by: United States Patent Patent 11,278,544

CONTRAVE is a drug marketed by Nalpropion. There are twenty patents protecting this drug and one Paragraph IV challenge.

This drug has two hundred and sixty-six patent family members in forty-four countries. There has been litigation on patents covering CONTRAVE

See drug price trends for CONTRAVE.

The generic ingredient in CONTRAVE is bupropion hydrochloride; naltrexone hydrochloride. There are thirty-eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the bupropion hydrochloride; naltrexone hydrochloride profile page.

Generic name: spinosad
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

NATROBA is a drug marketed by Parapro Llc. There are two patents protecting this drug.

This drug has thirty-seven patent family members in twenty-eight countries.

See drug price trends for NATROBA.

The generic ingredient in NATROBA is spinosad. There is one drug master file entry for this API. Two suppliers are listed for this generic product. Additional details are available on the spinosad profile page.

Generic name: midostaurin
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 28, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

RYDAPT is a drug marketed by Novartis. There are two patents protecting this drug. One tentatively approved generic is ready to enter the market.

This drug has sixty-two patent family members in twenty-seven countries. There has been litigation on patents covering RYDAPT

See drug price trends for RYDAPT.

The generic ingredient in RYDAPT is midostaurin. One supplier is listed for this generic product. Additional details are available on the midostaurin profile page.

Generic name: cupric sulfate; manganese sulfate; selenious acid; zinc sulfate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: April 30, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TRALEMENT is a drug marketed by Am Regent.

This drug has sixty-two patent family members in twenty-seven countries.

See drug price trends for TRALEMENT.

The generic ingredient in TRALEMENT is cupric sulfate; manganese sulfate; selenious acid; zinc sulfate. One supplier is listed for this generic product. Additional details are available on the cupric sulfate; manganese sulfate; selenious acid; zinc sulfate profile page.

Generic name: edaravone
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 05, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

RADICAVA is a drug marketed by Mitsubishi Tanabe. There are three patents protecting this drug.

This drug has sixty-two patent family members in twenty-seven countries.

See drug price trends for RADICAVA.

The generic ingredient in RADICAVA is edaravone. One supplier is listed for this generic product. Additional details are available on the edaravone profile page.

Generic name: peginesatide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 12, 2024
Generic Entry Controlled by: United States Patent Patent 7,084,245

OMONTYS is a drug marketed by Takeda Pharms Usa. There are six patents protecting this drug.

This drug has one hundred and fourteen patent family members in thirty-four countries.

The generic ingredient in OMONTYS is peginesatide acetate. Additional details are available on the peginesatide acetate profile page.

Generic name: benzyl alcohol
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 19, 2024
Generic Entry Controlled by: United States Patent Patent 7,294,342

ULESFIA is a drug marketed by Shionogi Inc. There is one patent protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering ULESFIA

The generic ingredient in ULESFIA is benzyl alcohol. There are fifty drug master file entries for this API. Additional details are available on the benzyl alcohol profile page.

Generic name: loxapine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 20, 2024
Generic Entry Controlled by: United States Patent Patent 9,370,629

ADASUVE is a drug marketed by Alexza Pharms. There are five patents protecting this drug.

This drug has two hundred and twenty-seven patent family members in twenty-one countries. There has been litigation on patents covering ADASUVE

See drug price trends for ADASUVE.

The generic ingredient in ADASUVE is loxapine. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the loxapine profile page.

Generic name: chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: May 25, 2024
Generic Entry Controlled by: United States Patent Patent 10,238,640

CHILDREN'S ADVIL ALLERGY SINUS is a drug marketed by Glaxosmithkline. There is one patent protecting this drug.

This drug has nine patent family members in eight countries.

The generic ingredient in CHILDREN'S ADVIL ALLERGY SINUS is chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride. There are twenty-nine drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the chlorpheniramine maleate; ibuprofen; pseudoephedrine hydrochloride profile page.

Generic name: aminolevulinic acid hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

GLEOLAN is a drug marketed by Nxdc.

This drug has nine patent family members in eight countries.

See drug price trends for GLEOLAN.

The generic ingredient in GLEOLAN is aminolevulinic acid hydrochloride. There are six drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the aminolevulinic acid hydrochloride profile page.

Generic name: nepafenac
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 08, 2024
Generic Entry Controlled by: United States Patent Patent 7,947,295

ILEVRO is a drug marketed by Harrow Eye. There are three patents protecting this drug and one Paragraph IV challenge.

This drug has ninety-four patent family members in twenty-six countries. There has been litigation on patents covering ILEVRO

See drug price trends for ILEVRO.

The generic ingredient in ILEVRO is nepafenac. There are eight drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the nepafenac profile page.

Generic name: bremelanotide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 21, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

VYLEESI (AUTOINJECTOR) is a drug marketed by Palatin Technologies. There are five patents protecting this drug.

This drug has seventy-nine patent family members in twenty-five countries.

The generic ingredient in VYLEESI (AUTOINJECTOR) is bremelanotide acetate. One supplier is listed for this generic product. Additional details are available on the bremelanotide acetate profile page.

Generic name: triptorelin pamoate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: June 29, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

TRIPTODUR KIT is a drug marketed by Azurity. There is one patent protecting this drug.

This drug has forty-six patent family members in thirty-one countries.

The generic ingredient in TRIPTODUR KIT is triptorelin pamoate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the triptorelin pamoate profile page.

Generic name: l-glutamine
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 07, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ENDARI is a drug marketed by Emmaus Medcl. One tentatively approved generic is ready to enter the market.

This drug has forty-six patent family members in thirty-one countries.

See drug price trends for ENDARI.

The generic ingredient in ENDARI is l-glutamine. There are forty-five drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the l-glutamine profile page.

Generic name: dalbavancin hydrochloride
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: July 22, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

DALVANCE is a drug marketed by Abbvie. There are four patents protecting this drug.

This drug has fifty-eight patent family members in twenty countries.

See drug price trends for DALVANCE.

The generic ingredient in DALVANCE is dalbavancin hydrochloride. One supplier is listed for this generic product. Additional details are available on the dalbavancin hydrochloride profile page.

Generic name: oritavancin diphosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

KIMYRSA is a drug marketed by Melinta Therap. There are three patents protecting this drug.

This drug has thirty-nine patent family members in seventeen countries.

See drug price trends for KIMYRSA.

The generic ingredient in KIMYRSA is oritavancin diphosphate. One supplier is listed for this generic product. Additional details are available on the oritavancin diphosphate profile page.

Generic name: oritavancin diphosphate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: August 06, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ORBACTIV is a drug marketed by Melinta Therap. There are three patents protecting this drug.

This drug has thirty-nine patent family members in seventeen countries.

See drug price trends for ORBACTIV.

The generic ingredient in ORBACTIV is oritavancin diphosphate. One supplier is listed for this generic product. Additional details are available on the oritavancin diphosphate profile page.

Generic name: elagolix sodium,estradiol,norethindrone acetate; elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 10, 2024
Generic Entry Controlled by: United States Patent Patent 7,056,927

ORIAHNN (COPACKAGED) is a drug marketed by Abbvie. There are seven patents protecting this drug.

This drug has fifty-five patent family members in twenty-three countries. There has been litigation on patents covering ORIAHNN (COPACKAGED)

The generic ingredient in ORIAHNN (COPACKAGED) is elagolix sodium,estradiol,norethindrone acetate; elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium,estradiol,norethindrone acetate; elagolix sodium profile page.

Generic name: elagolix sodium
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 10, 2024
Generic Entry Controlled by: United States Patent Patent 7,056,927

ORILISSA is a drug marketed by Abbvie. There are ten patents protecting this drug.

This drug has ninety-five patent family members in twenty-six countries. There has been litigation on patents covering ORILISSA

See drug price trends for ORILISSA.

The generic ingredient in ORILISSA is elagolix sodium. One supplier is listed for this generic product. Additional details are available on the elagolix sodium profile page.

Generic name: lanreotide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 15, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

SOMATULINE DEPOT is a drug marketed by Ipsen Pharma.

This drug has ninety-five patent family members in twenty-six countries.

The generic ingredient in SOMATULINE DEPOT is lanreotide acetate. There are three drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the lanreotide acetate profile page.

Generic name: granisetron
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: September 28, 2024
Generic Entry Controlled by: United States Patent Patent 8,715,710

SUSTOL is a drug marketed by Heron Theraps Inc. There are five patents protecting this drug.

This drug has eighteen patent family members in ten countries.

See drug price trends for SUSTOL.

The generic ingredient in SUSTOL is granisetron. There are twenty-six drug master file entries for this API. Two suppliers are listed for this generic product. Additional details are available on the granisetron profile page.

Generic name: ziconotide acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 01, 2024
Generic Entry Controlled by: United States Patent Patent 5,364,842

PRIALT is a drug marketed by Tersera. There are three patents protecting this drug.

This drug has six patent family members in four countries.

See drug price trends for PRIALT.

The generic ingredient in PRIALT is ziconotide acetate. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the ziconotide acetate profile page.

Generic name: ascorbic acid
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 02, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

ASCOR is a drug marketed by Mcguff.

This drug has six patent family members in four countries.

See drug price trends for ASCOR.

The generic ingredient in ASCOR is ascorbic acid. There are six drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the ascorbic acid profile page.

Generic name: fluorodopa f-18
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: October 10, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

FLUORODOPA F18 is a drug marketed by Feinstein.

This drug has six patent family members in four countries.

The generic ingredient in FLUORODOPA F18 is fluorodopa f-18. One supplier is listed for this generic product. Additional details are available on the fluorodopa f-18 profile page.

Generic name: exenatide synthetic
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 04, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

BYETTA is a drug marketed by Astrazeneca Ab.

This drug has six patent family members in four countries. There has been litigation on patents covering BYETTA

See drug price trends for BYETTA.

The generic ingredient in BYETTA is exenatide synthetic. There are seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the exenatide synthetic profile page.

Generic name: air polymer-type a
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 07, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

EXEM FOAM KIT is a drug marketed by Giskit. There are three patents protecting this drug.

This drug has six patent family members in six countries.

The generic ingredient in EXEM FOAM KIT is air polymer-type a. There are thirty-seven drug master file entries for this API. One supplier is listed for this generic product. Additional details are available on the air polymer-type a profile page.

Generic name: istradefylline
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: November 13, 2024
Generic Entry Controlled by: United States Patent Patent 7,541,363

NOURIANZ is a drug marketed by Kyowa Kirin. There are four patents protecting this drug.

This drug has sixty-three patent family members in eighteen countries.

See drug price trends for NOURIANZ.

The generic ingredient in NOURIANZ is istradefylline. There is one drug master file entry for this API. One supplier is listed for this generic product. Additional details are available on the istradefylline profile page.

Generic name: macimorelin acetate
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

MACRILEN is a drug marketed by Novo. There is one patent protecting this drug.

This drug has eleven patent family members in ten countries.

See drug price trends for MACRILEN.

The generic ingredient in MACRILEN is macimorelin acetate. Two suppliers are listed for this generic product. Additional details are available on the macimorelin acetate profile page.

Generic name: rivaroxaban
DrugPatentWatch^® Estimated Key Patent Expiration / Generic Entry Date: December 20, 2024
Generic Entry Controlled by: United States FDA Regulatory Exclusivity

XARELTO is a drug marketed by Janssen Pharms. There are five patents protecting this drug and two Paragraph IV challenges. Four tentatively approved generics are ready to enter the market.

This drug has one hundred and fifty-six patent family members in forty-seven countries. There has been litigation on patents covering XARELTO

See drug price trends for XARELTO.

The generic ingredient in XARELTO is rivaroxaban. There are thirty-five drug master file entries for this API. Three suppliers are listed for this generic product. Additional details are available on the rivaroxaban profile page.